Description
Brand-Name Medication Track
$99 per month — monthly care fee
Prescription included; medication cost not included. If eligible, medications may be covered with a copay or start at $299 self-pay
Transform your weight-loss journey with GLP-1 therapies clinically proven to regulate appetite and promote sustainable fat loss. Options include Wegovy, Ozempic, Zepbound, and compounded or oral GLP-1 formulations.
Program Features:
• Monthly GLP-1 prescription & medication support
• Ongoing medical oversight
• Body composition tracking & adjustments
A comprehensive, supportive, and medically supervised pathway to safe and effective weight loss.
FAQ: Zepbound™ and the CWMD Weight Loss Program
What is Zepbound™?
Zepbound™ (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist originally approved for the treatment of type 2 diabetes. It functions by mimicking a hormone that targets areas of the brain involved in appetite regulation.
How does Zepbound™ work?
Zepbound™ works by slowing gastric emptying, enhancing feelings of fullness, and reducing appetite, which can help manage weight when combined with diet and exercise.
Will insurance cover Zepbound™?
Coverage depends on your insurance plan and whether Zepbound™ is prescribed for an FDA-approved use. Coastal Wellness MD offers a initial consultation to navigate insurance or explore self-pay options.
Can I get a Zepbound™ prescription through Coastal Wellness MD?
Zepbound™ is FDA-approved for some adults who are overweight with other weight-related medical problems, to help them lose excess body weight and keep the weight off. It may be prescribed by a Coastal Wellness MD provider as part of your weight management program.
Which GLP-1 is right for you?
Choosing a GLP-1 medication like Zepbound™ depends on individual health history and insurance coverage. Your Coastal Wellness MD provider can help determine the best option for your weight loss journey.
Reviews
There are no reviews yet.